Biotech Otologic Pharmaceuticals has chosen North Carolina's PharPoint Research to run an early trial of its lead candidate, a treatment for hearing loss.
Johnson & Johnson has deepened its ties to regenerative medicine outfit ViaCyte, handing the biotech $20 million in exchange for a future stake in the company and the right to acquire its in-development diabetes medication.
Bristol-Myers Squibb and Celgene are joining forces on a cancer combination treatment, testing the former's highly anticipated immunotherapy in tandem with an on-the-market chemo drug against a host of tumor targets.
German drug developer MorphoSys is pairing up with Emergent BioSolutions to get its hands on an early-stage prostate cancer treatment, signing a deal worth up to $183 million for a promising antibody.
Boston Scientific has just announced plans to launch new fractional flow reserve and atherectomy guidewires in 2015 in collaboration with Japanese medical component specialist Asahi Intecc.
Big Pharma is interested in partnering with startup electroCore on commercializing its noninvasive vagus nerve stimulation therapy for migraines and cluster headaches upon FDA approval, company CEO JP Errico says. In a sign that talks may be heating up, electroCore has appointed investment bank Piper Jaffray to advise it.
Maryland CRO ABL has signed a deal with Expression Therapeutics to to handle cell line development studies and help the biotech produce a treatment for hemophilia A.
Pfizer is reaching out to the Google-backed genomics outfit 23andMe to better understand the root causes of inflammatory bowel disease, looking to mine patient data for clues that could bolster its growing pipeline.
Ophthalmology company Oraya Therapeutics will collaborate with researchers from Boston's Dana-Farber Cancer Institute to study applications of its novel radiation therapy against cancer when used in conjunction with gold nanoparticles.
Medtronic quietly hired former Sens. John Breaux (D-LA) and Trent Lott (R-MS) and three others as lobbyists to combat anti-inversion legislation as political anger over the tax saving method mounts, threatening the planned company's planned merger with Covidien.